- Home
- NET vs ARGX Comparison
NET vs ARGX Comparison
Compare NET & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NET
- ARGX
- Stock Information
- Founded
- NET 2009
- ARGX 2008
- Country
- NET United States
- ARGX Netherlands
- Employees
- NET N/A
- ARGX N/A
- Industry
- NET Computer Software: Prepackaged Software
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NET Technology
- ARGX Health Care
- Exchange
- NET Nasdaq
- ARGX Nasdaq
- Market Cap
- NET 39.6B
- ARGX 37.3B
- IPO Year
- NET 2019
- ARGX 2017
- Fundamental
- Price
- NET $112.64
- ARGX $623.82
- Analyst Decision
- NET Hold
- ARGX Strong Buy
- Analyst Count
- NET 26
- ARGX 20
- Target Price
- NET $98.72
- ARGX $634.50
- AVG Volume (30 Days)
- NET 2.9M
- ARGX 290.3K
- Earning Date
- NET 02-06-2025
- ARGX 10-31-2024
- Dividend Yield
- NET N/A
- ARGX N/A
- EPS Growth
- NET N/A
- ARGX N/A
- EPS
- NET N/A
- ARGX N/A
- Revenue
- NET $1,572,153,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- NET $29.40
- ARGX $61.99
- Revenue Next Year
- NET $25.74
- ARGX $42.48
- P/E Ratio
- NET N/A
- ARGX N/A
- Revenue Growth
- NET 30.04
- ARGX 85.56
- 52 Week Low
- NET $66.24
- ARGX $349.86
- 52 Week High
- NET $119.42
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- NET 59.68
- ARGX 58.04
- Support Level
- NET $107.00
- ARGX $613.95
- Resistance Level
- NET $119.42
- ARGX $644.97
- Average True Range (ATR)
- NET 4.17
- ARGX 14.33
- MACD
- NET -0.64
- ARGX -0.42
- Stochastic Oscillator
- NET 58.17
- ARGX 50.28
About NET Cloudflare Inc.
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.